Obesity: Evaluation and treatment

Disease-a-Month

Volumn 42, Issue 12, 1996, Pages 829-873

  Blocker, William P ^a   Ostermann, Henry J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT;

HUMAN; MORBID OBESITY; OBESITY; PATHOPHYSIOLOGY; REVIEW; TREATMENT FAILURE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; HUMANS; OBESITY; OBESITY, MORBID; TREATMENT FAILURE; WEIGHT LOSS;

EID: 0030345183     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(96)80001-0     Document Type: Article

References (94)

1. The food resources in the earth and man
2. Settlement of the first farmer: the last two million years
3. The origins of medicine in prehistory and primitive people
4. The origins of medicine in prehistory and primitive people
5. Coronary risk factors
6. Obesity: the most common factor in coronary heart disease
7. Severe obesity
8. Childhood obesity
9. Trends in fatness and the origin of obesity
10. Complication of obesity
11. The obese patient: major problems
12. Health implications of obesity
13. Medical implications of obesity
14. Nutritional disorders in the obese patient
15. Genetic and environmental factors in the development of human obesity: the genetics of obesity
16. Body build and its inheritance
17. Endocrinology in obesity
18. The management of obesity
19. Micronutrients and energy balance in obesity
20. The neuroanatomy of eating and drinking behavior
21. Neuropeptides, appetite regulation and human obesity
22. Hunger and appetite
23. Obesity
24. Human body composition and epidemiology of chronic diseases
25. Epidemiology of obesity and its link to heart disease
26. The heart in obesity
27. Mechanisms of hypertension associated with obesity
28. The effects of overweight on cardivascular disease
29. The effects of weight reduction on left ventricular mass
30. Cardiopathy of obesity: a not so Victorian disease
31. Health implications of obesity in USA
32. Epidemiology of smoring and its consequences
33. Renal disease in patients with massive obesity
34. Normal abnormalities in obesity
35. The effect of obesity on postmenopausal bone loss and the risk of osteoporosis
36. Endocrine abnormalities in obesity
37. Insulin resistance: a multifaceted syndrome for NIDDM, obesity, hypertension, dyslipedemia in cardiac disease
38. Timing of weight gain to breast cancer risk
39. Excessive mortality and cause of death in morbidly obese men
40. Obesity and cancer
41. Gastrointestinal motility in obesity
42. Role of the sympathetic nervous system in blood pressure maintenance in obesity
43. The cardiovascular consequences of prolonged obesity
44. Obesity and hypertension: roles of hyperinsulism, sympathetic nervous system
45. Weight and hypertension. II
46. Variations in mortality among 750,000 men and women
47. Obesity in men and women
48. Medical management of obesity
49. Emotional aspects of obesity
50. Social-psychological prospective in motivating behavior
51. Behavioral science and nutrition in new prospective
52. Eating disorders
53. Severe obesity: expensive to society, frustrating to treat, but important to confront
54. Childhood pathophysiology and treatment
55. A very low caloric diet: their efficacy, safety and future
56. Caution: very low caloric diets
57. Very low caloric diet and EKG changes
58. Starvation: metabolic and physiologic responses
59. Biological adaptations to starvation and semistarvation
60. Effects of aerobic exercises on energy expenditures and nitrogen balance during very low caloric diet
61. Nitrogen and sodium balance and sympathetic system in obese subjects on low caloric diet protein diet
62. Behavioral treatment of obesity
63. Limitation of behavioral treatment of obesity
64. A case for drug treatment of obesity
65. The treatment of obesity (fenfluramine)
66. Diethylproprion: an appetite suppressant
67. Pharmacological treatment of obesity
68. Obesity
69. A double blind clinical trial in weight control: use fenfluramine and phenteramine alone and in combination
70. Psychomimetic effects of anoretic drugs
71. FDA may ease approval rules for diet drugs
72. Physical activity in development and control of obesity
73. When your obese patient can't lose weight
74. Food records: a predictor and modifier of weight changes in long term weight loss program
75. How accurate is self reporting dietary energy intake?
76. Understanding and improving patient compliance
77. Weight loss plateaus: questions and answers
78. Effects of exercise and food restriction on body composition and metabolic rate in obese women
79. Effects of carbohydrate and aerobic exercise during weight reduction
80. Antidepressants and weight gain
81. Gastric balloon implementation for weight loss in the morbidly obese
82. Gastrointestinal surgery for severe obesity: National Institutes of Health consensus development conference draft statement on gastrointestinal surgery for severe obesity
83. Surgery for morbid obesity
84. Preoperative insurance status influencing postoperative complication rates for gastric bypass
85. Gastric bypass in obesity
86. Long term cost comparison of gastric bypass versus intensive medical and behavioral therapy for morbidly obese patients
87. Liposuction: what it will and won't do
88. The risks of suction lipectomy: their prevention and treatment